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Emerging Topics
The Clinical Review Committee: Impact of
the Development of In Vitro Diagnostic Tests
for SARS-CoV-2 Within RADx Tech
Matthew L. Robinson , Charlotte Gaydos, Barbara Van Der Pol, Sally McFall, Yu-Hsiang Hsieh,
William Clarke, Robert L. Murphy, Lea E. Widdice, Lisa R. Hirschhorn, Richard Rothman,
Chad Achenbach, Claudia Hawkins, Adam Samuta, Laura Gibson, David D. McManus,
and Yukari C. Manabe
Abstract—The NIH Rapid Acceleration of Diagnostics
(RADxSM) Tech Program was created to speed the devel-
opment, validation, and commercialization of innovative
point-of-care (POC) and home-based tests, and to improve
clinical laboratory tests, that can directly detect SARS-CoV-
2. Leveraging the experience of the Point-of-Care Tech-
nologies Research Network, a Clinical Review Committee
(CRC) composed of clinicians, bioengineers, regulatory ex-
perts, and laboratorians was created to provide structured
feedback to SARS-CoV-2 diagnostic innovators. The CRC
convened 53 meetings with 49 companies offering SARS-
CoV-2 tests in POC and reference laboratory formats as
well as collection materials. The CRC identified common
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barriers to device design finalization including biosafety,
workflow, result reporting, regulatory requirements, sample
type, supply chain, limit of detection, lack of relevant valida-
tion data, and price-performance-use mismatch. Feedback
from companies participating was positive.
Index Terms—SARS-CoV-2, COVID-19, in vitro diagnos-
tics, point-of-care testing, Rapid Acceleration of Diagnos-
tics program.
Impact Statement—As part of the NIH Rapid Acceleration
of Diagnostics (RADxSM) Tech Program, structured feed-
back from the Clinical Review Committee allowed device
companies to identify common design challenges and im-
prove their assays.
I. INTRODUCTION
The average in vitro diagnostic assay usually takes nearly
10 years to progress from proof-of-concept feasibility to full
evaluation. [1] One year into the pandemic, the demand for
SARS-CoV-2 testing continues to vastly exceed supply - less
than 2 million SARS-CoV-2 tests are performed daily in the
United States, yet 10 million tests per day will be required
to safely open schools, and more will be required to interrupt
widespread transmission. [2], [3] In order to accelerate the
deployment of SARS-CoV-2 assays including rapid, point-of-
care (POC) tests within the National Institutes of Health (NIH)
Rapid Acceleration of Diagnostics (RADxSM) Tech Program,
an understanding of each device’s use case is necessary. How
a device will be used informs early development, avoids costly
delays and changes in design and workflow, and maximizes the
public health benefit from its deployment.
Diagnostic innovators rarely have access to broad use case ex-
pertise including clinicians in multiple specialties, bioengineers,
regulatory experts, laboratorians, and business leaders. The ex-
perience of the National Institutes of Health (NIH) National
Institute of Biomedical Imaging and Bioengineering (NIBIB)-
funded POC Technologies Research Network (POCTRN) has
demonstrated that lack of early and granular feedback on in-
tended device use case by expert users exposes novel diagnostics
to subsequent development bottlenecks created by unanticipated
clinical challenges, systems engineering and technical usability
flaws, cumbersome workflows, and insufficient validation. [4]
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Companies applying to the RADx Tech opportunity were ini-
tially selected based on scientific innovation and early proof-
of-concept performance data. The Clinical Review Committee
(CRC) conducted assessments prior to design finalization to
support accelerated development of SARS-CoV-2 diagnostics
in the RADx Tech portfolio.
II. METHODS
We assembled a CRC comprised of 14 members includ-
ing infectious disease, emergency medicine, ambulatory, pe-
diatric, and adult clinicians, laboratorians, and diagnostic test
and marketing experts with real-world bedside and clinical
laboratory COVID-19 experience. Every RADx Tech-funded
company at any stage beyond proof-of-concept was offered
a 1-hour facilitated meeting with the CRC to provide struc-
tured feedback. Each company presented their one technologic
approach to COVID-19 diagnosis, but also had the opportu-
nity to discuss earlier stage technologies if time permitted.
The CRC was intentional to not favor any specific diagnos-
tic approach. The previous experience of the POCTRN in
shepherding novel POC tests for sexually transmitted infections
including HIV from proof-of-concept to Food and Drug Admin-
istration (FDA) approval was leveraged to provide SARS-CoV-2
diagnostic developers with the infectious disease and use case
expertise necessary to understand how a test would be used
for decision-making by clinicians and other end users. Such
concepts of clinical usability and feasibility are as important to
success as test performance and accuracy. The template for CRC
meetings included a company presentation on the technology
and device including workflow (15 minutes), validation data (5
minutes), proposed sample type and use case discussion (10 min-
utes), business development (5 minutes), proposed pre-clinical
pilot study on performance (5 minutes), open discussion (15
minutes), and summary (5 minutes). Detailed written feedback
and recommendations from the 60-minute CRC meeting was
prepared by the Committee chairs and sent to each participating
company and NIH within one week.
The original CRC concept emphasized pre-meeting prepara-
tion including completion of an intake form by the company and
a preparatory conversation between committee chairs and the
RADx Tech Team Lead. [5] The intake form included structured
questions to characterize the detection technology, specimen
type, collection modality, device operation, performance, and
human factors characteristics. Based on the rapid pace of RADx
Tech and to avoid duplication of effort, all pre-meeting work
including the intake form was later eliminated. The written
feedback of the CRC based on notes taken during the meeting
evolved to include the following subsections: description of the
technology emphasizing innovation or novel aspects, validation
of performance (sensitivity, specificity, limit of detection, clin-
ical sample data vs. spiked matrix), potential use cases, issues
raised by the committee, business approach and pricing (cost of
goods compared to estimated commercial price), and summary
of the recommendations. Feedback from companies participat-
ing in CRC meetings was sought in the form of unstructured
communication with the CRC coordinator. The NIBIB proposed
that the CRC convene for 50 meetings. To facilitate scheduling
meetings and allow a high attendance rate of CRC standing
members, committee meetings were consistently scheduled at
8 am and 5 pm, allowing committee members to block their
schedules. Due to the geographic dispersal of companies and
teams, most meetings occurred at 5 PM Eastern Standard Time.
Meetings were held over a virtual video-conferencing platform.
III. RESULTS
From June 18, 2020 through December 18, 2020, 53 meet-
ings with 49 companies occurred. The CRC reviewed devices
intended for use in multiple settings including the POC (with
or without a device), reference labs, mobile vans, and sam-
ple collection and preparation workflows (Fig. 1). Detection
modalities included antigen detection, nucleic acid tests, con-
centration and capture, and others (Fig. 1). Between 4 and 12
committee members attended each meeting. Device company
representatives included leadership (CEO, marketing, scientific
developers, regulatory) as well as RADx Tech programmatic
leadership including the Team Lead, the Portfolio Executive,
FDA liaison, NIH representative, and other RADx Tech support
team members.
The majority of the meeting time was used for discussion
of device use workflow and suggestions for process improve-
ment rather than use case and pre-clinical pilot studies. For
the majority of assays discussed, lack of data on device perfor-
mance characteristics for clinical specimens led to uncertainty
around the viability of some of the devices. Common barriers
to design finalization included inadequate biosafety, complex
workflow, inadequate result reporting, difficulty meeting regu-
latory requirements, inappropriate sample types, supply chain
bottlenecks, lack of optimization of the limit of detection, lack
of validation data, and a mismatch of the proposed price with
performance and use case (Table 1).
Verbal summary by the facilitator at the end of the meeting de-
tailed the points raised by committee members, areas of certainty
and uncertainty, and how the company’s efforts to date have the
potential to address clinical and public health needs. Written
summaries provided companies with detailed documentation of
CRC discussion and recommendations.
Qualitative feedback from companies that participated in
the CRC process included appreciation that meetings occurred
early in the RADx Tech process before design finalization,
perspectives represented the voice of future customers, pointed
questions forced discussion of process improvement, and verbal
and written meeting summaries were helpful in the detail they
provided. The RADx Tech program benefited from CRC feed-
back as another reference point in tracking device development
progress and informed the design and conduct of clinical studies
performed by the RADx Tech Clinical Study Core.
IV. DISCUSSION
A series of joint meetings convened between 49 diagnostic
companies and a CRC with relevant expertise in the clinical,
laboratory, and practical challenges of infectious disease diag-
nostic use demonstrated a pattern of common barriers to design
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FIG. 1. Use case, detection modality, and sample type for the reviewed technologies. Each column of a fixed width represents a single reviewed
device, sorted by setting of intended use and then detection modality. Rows represent diagnostic features including detection modality followed by
intended sample types.
TABLE 1.
COMMON BARRIERS TO DESIGN FINALIZATION IDENTIFIED BY THE CRC
success. Granular questioning and feedback forced companies
to confront challenges at an early development stage, prior to
design finalization. The CRC was also able to highlight the
innovative or distinguishing features of promising technologies.
RADx Tech Team Leads learned important clinical and labo-
ratory user views on workflow allowing them to best advise
companies in their portfolios.
Optimization and feasibility testing require a clear under-
standing of the clinical need and the use case for the proposed
assay. For example, the rapidly evolving COVID-19 field has
already shown that an early reliance on nasopharyngeal swabs
is being supplanted by oropharyngeal swabs [6], [7], nasal
mid-turbinate swabs, sputum [8] and now saliva [9], [10] for
molecular nucleic acid amplification tests as well as salivary
antigen testing. [11] Self-collection versus clinician collection is
also being investigated. [12] The relative sensitivity of different
sample types, point of collection, severity of disease (hospi-
talized, ambulatory, asymptomatic) is a complicated landscape
that is evolving at an unprecedented pace given the novelty of
SARS-CoV-2 in aspects of its virology and clinical course of
infection.
RADx-Tech funded companies originally viewed their in-
volvement in CRC meetings as a necessary hurdle along the
RADx Tech pipeline, but qualitative feedback on the sessions
showed that company representatives appreciated the opportu-
nity and challenge of considering the ‘next step of the project.’
In-depth review by the convened CRC members is a rare resource
for small start-up companies; larger companies benefited from
real-world, diverse viewpoints from a multidisciplinary team
outside of the potentially closed perspective of industry. The
CRC may serve as a model for how to quickly support clin-
ical diagnostic assay development for other urgent diagnostic
challenges in the future.
V. NEXT STEPS
As a next step, the CRC intends to perform assessment of
the adoption and impact of specific recommendations to par-
ticipating companies on their progression through RADx Tech
portfolio milestones. Additional analysis of the feasibility of
early risk stratification on the basis of common assessment areas
will also be performed.
VI. CONCLUSION
Common barriers to design finalization for SARS-CoV-2
diagnostic devices that were identified by the CRC included
biosafety considerations, complicated workflows, lack of vali-
dation with real clinical specimens, and lack of clinical input on
sample type and use case. Addressing risks identified by a mul-
tidisciplinary group of infectious disease and use case experts
after proof-of-concept, yet early in development, has value for
companies. A Clinical Review Committee when convened early
in development helps companies avoid potentially costly design
issues (go-no go, pivot).
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